|
|
|
| Effect of Compound Kushen Injection Combined with Docetaxel on NSCLC Patient after the Failure of First-line Chemotherapy Treatment |
| BAI Jing |
| The JinTan District People's Hospital of Changzhou city, Jiangsu Province, 213200 |
|
|
|
|
Abstract 【Objective】To investigate the effect of compound Kushen injection combined with Docetaxel on serum tumor markers in patients with non-small cell lung cancer (NSCLC) after the failure of first-line chemotherapy treatment.【Methods】A total of 80 patients with NSCLC after the failure of first-line chemotherapy treatment were randomly divided into observation group (treated with compound Kushen injection combined with docetaxel) and control group (treated with docetaxel). The short-term efficacy, adverse reactions, serum tumor markers levels before and after treatment and changes of cellular immune function were compared between the two groups, OS and PFS of the two groups were statistically analyzed.【Results】The short-term effective rate and disease control rate of the observation group were 25% (10/25) and 62.50% (25/40), respectively, which were significantly higher than 10% (4/40) and 37.50% (15, 40) of the control group, and the difference was significant (P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05);Compared with before treatment, the levels of serum carcinoembryonic antigen (CEA), carbohydrate antigen -125 (CA-125) and cytokeratin 19 fragment (CYFRA21 - 1) were significantly decreased in the two groups after treatment (P<0.05), and the above indexes in the observation group were significantly lower than those in the control group (P<0.05);The median OS and PFS in the observation group were 13.50 months and 9 months respectively, which were significantly longer than those in the control group at 10.20 months and 7.40 months, and the difference was significant (P<0.05).【Conclusion】Compound Kushen injection combined with docetaxel can significantly reduce the serum tumor markers in patients with NSCLC, improve the cellular immune function, prolong OS, PFS, and do not increase toxicity
|
|
Received: 06 March 2017
|
|
|
|
|
|
[1]张艳林,杨梅,陈麦林,等.CT动态增强扫描定量参数与非小细胞肺癌患者靶向治疗效果的相关性研究[J].中国CT和MRI杂志,2013,11(6):48-51.
[2]郝杰,曾葭.多西他赛单药每周方案与GP方案治疗老年晚期非小细胞肺癌的疗效比较[J].医学临床研究,2010,27(2):233-234,238.
[3]杨杨.益气解毒法结合化疗对晚期非小细胞肺癌临床疗效分析及对T细胞亚群和NK细胞活性的影响[J].四川中医,2015,33(1):84-86.
[4]王纯,卢宏达.新辅助化疗对局部晚期非小细胞肺癌肿瘤标记物和淋巴细胞亚群的影响[J].重庆医学,2014,43(1):61-63,66.
[5]沈富林,金家贵,曹凤军,等.中医药联合同步放化疗治疗Ⅲ期非小细胞肺癌临床观察[J].西部医学,2014,26(4):445-446,449.
[6]刘敏,康婷,段伟,等.复方苦参注射液联合化疗对晚期非小细胞肺癌患者毒副反应及免疫功能的影响[J].实用临床医药杂志,2014,18(23):29-31.
[7]赵丽敏,吴纪珍,马利军,等.复方苦参注射液对中、晚期非小细胞肺癌化疗患者免疫功能的影响[J].山东医药,2011,51(5):102.
[8]卢虎生,陆林,徐秀理,等.NSCLC 放疗前后血清中 CEA、CYFRA21-1及 NSE 的水平变化与疗效评价[J].湖南师范大学学报(医学版),2016,13(2):114-116,117. |
|
|
|
2017, Vol. 34 
